Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo ( n = 40 ) or erlotinib ( 100mg , n = 40 ) given concurrently with WBRT ( 20 Gy in 5 fractions ) .